Host: Cem Akin, MD, PhD Guest: Deepti Radia, MD Indolent systemic mastocytosis is a rare disease often overlooked in the general healthcare setting. Drs. Deepti Radia and Cem Akin outline diagnostic criteria, signs and symptoms, and diagnostic test

Host: Robert L. Coleman, MD, FACOG, FACS Guest: Kathleen Moore, MD, MS The global burden of cervical cancer is immense, especially for patients who have failed first-line therapy. Second-line interventions have historically had low response rates o

Host: Donna Ryan, MD Guest: Juan Pablo Frías, MD There are now multiple medical therapies available to facilitate weight loss in patients with type 2 diabetes (T2D). Learn who is the right patient, when these therapies should be started, and the ri

Host: Christina Y. Weng, MD, MBA Guest: Margaret A. Chang, MD, MS What are the critical steps to implantation and refill of the PDS? Join Dr. Margaret Chang and Dr. Christina Weng to discover the nuances that retina surgeons need to know about to o

Host: David Eichenbaum, MD Guest: Mark R. Barakat, MD Several novel treatment options are now available for DME, but do you know how which patients to treat with these agents to prolong durability and improve access? Join Dr. David Eichenbaum and D

Guest: Neera Dahl, MD, PhD Guest: Craig E. Gordon, MD This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.

Host: David Eichenbaum, MD Guest: Mark R. Barakat, MD Several novel treatment options are now available for DME, but do you know how which patients to treat with these agents to prolong durability and improve access? Join Dr. David Eichenbaum and D

Host: John Kitchens, MD Guest: SriniVas R. Sadda, MD Whether you’re a medical or surgical retina specialist, the port delivery system (PDS) is a practice-changing treatment modality. How can you smoothly incorporate continuous anti-VEGF delivery te

Host: Suzanne J. Baron, MD Guest: Jonathan A. Bradlow, MD, FACC Guest: Kendra J. Grubb, MD Data are limited on the incidence and factors associated with structural valve deterioration (SVD) after transcatheter aortic valve replacement (TAVR) and

Host: Cem Akin, MD, PhD Guest: Jason Gotlib, MD, MS It could take up to 7 years for a patient to be accurately diagnosed with systemic mastocytosis. Drs. Jason Gotlib and Cem Akin take us through the guidelines, diagnostic criteria, signs and sympt